Novavax: launches phase 2 trial

(CercleFinance.com) - The biotech company Novavax has announced the launch of a phase 2 trial for its influenza vaccine candidates against influenza alone and against Covid-19 and influenza together.


The trial will aim to enrol a total of approximately 2,300 participants and will evaluate the safety and efficacy (immunogenicity) of different formulations of these candidate vaccines in adults aged 50 to 80 years. The first results are expected in mid-2023.

It is encouraged by the positive results reported earlier in the year from its Phase 1/2 trial, which is the first of its kind to evaluate a combined Covid-19 and influenza vaccine, it said.



Copyright (c) 2022 CercleFinance.com. All rights reserved.